Yi Y - Search Results

1

Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis.

Zhang J, Yang F, Li B, Li H, Liu J, Huang W, Wang D, Yi Y, Wang J. Zhang J, et al. Among authors: yi y. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e305-16. doi: 10.1016/j.ijrobp.2011.04.034. Epub 2011 Jun 12. Int J Radiat Oncol Biol Phys. 2011. PMID: 21658853 Review.

2

Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma.

Li BS, Zhou T, Wang ZT, Li HS, Sun HF, Zhang ZC, Lin HQ, Wei YM, Gong HY, Huang W, Yi Y, Wang LY. Li BS, et al. Among authors: yi y. Radiother Oncol. 2009 Dec;93(3):458-61. doi: 10.1016/j.radonc.2009.08.002. Epub 2009 Sep 3. Radiother Oncol. 2009. PMID: 19733411 Clinical Trial.

3

CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.

Yi Y, Li B, Wang Z, Sun H, Gong H, Zhang Z. Yi Y, et al. Biomarkers. 2009 Nov;14(7):480-5. doi: 10.3109/13547500903180265. Biomarkers. 2009. PMID: 19863186

4

Predictors of sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma.

Yi Y, Li B, Sun H, Zhang Z, Gong H, Li H, Huang W, Wang Z. Yi Y, et al. Tumour Biol. 2010 Aug;31(4):333-40. doi: 10.1007/s13277-010-0041-9. Epub 2010 May 20. Tumour Biol. 2010. PMID: 20490963

5

Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume delineation of regional lymph node in patients with gastric carcinoma.

Yi Y, Yu J, Li B, Yang F, Huang W, Sun H, Gong H, Zhou T, Lin H. Yi Y, et al. Radiother Oncol. 2010 Aug;96(2):223-30. doi: 10.1016/j.radonc.2010.04.031. Epub 2010 Jun 30. Radiother Oncol. 2010. PMID: 20584555

6

CYFRA21-1 can predict the sensitivity to chemoradiotherapy of non-small-cell lung carcinoma.

Wang J, Yi Y, Li B, Wang Z, Sun H, Zhang P, Huang W. Wang J, et al. Among authors: yi y. Biomarkers. 2010 Nov;15(7):594-601. doi: 10.3109/1354750X.2010.504308. Epub 2010 Jul 23. Biomarkers. 2010. PMID: 20649505

7

Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: a probable predictive factor for tumor response.

Wang J, Zhang N, Li B, Wang Z, Sun H, Yi Y, Huang W. Wang J, et al. Among authors: yi y. Tumour Biol. 2011 Aug;32(4):689-95. doi: 10.1007/s13277-011-0169-2. Epub 2011 Mar 16. Tumour Biol. 2011. PMID: 21409421

8

Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer.

Li BS, Gong HY, Huang W, Yi Y, Yu JM, Wang ZT, Zhang ZC, Sun HF, Li HS, Wang LY. Li BS, et al. Among authors: yi y. Am J Clin Oncol. 2012 Apr;35(2):115-9. doi: 10.1097/COC.0b013e318209ab93. Am J Clin Oncol. 2012. PMID: 21555933 Clinical Trial.

9

Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers.

Ding XP, Zhang J, Li BS, Li HS, Wang ZT, Yi Y, Sun HF, Wang DQ. Ding XP, et al. Among authors: yi y. Asian Pac J Cancer Prev. 2012;13(1):319-23. doi: 10.7314/apjcp.2012.13.1.319. Asian Pac J Cancer Prev. 2012. PMID: 22502693 Free article.

10

A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.

Ding X, Li H, Wang Z, Huang W, Li B, Zang R, Sun H, Yi Y. Ding X, et al. Among authors: yi y. Technol Cancer Res Treat. 2013 Jun;12(3):251-7. doi: 10.7785/tcrt.2012.500310. Epub 2012 Dec 26. Technol Cancer Res Treat. 2013. PMID: 23289475 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,736 results

Search Page

Filters